MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

Rhea-AI Summary

MacroGenics, Inc. (MGNX) will release its Q4 2023 financial results on March 7, 2024. The company focuses on developing antibody-based therapeutics for cancer treatment. A conference call discussing financial results and corporate progress will be held on the same day at 4:30 pm ET.

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET.

Conference Call Information

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

When will MacroGenics release its financial results for Q4 2023?

MacroGenics will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024.

What is MacroGenics' focus in terms of therapeutics development?

MacroGenics focuses on developing antibody-based therapeutics for the treatment of cancer.

When will the conference call discussing financial results and corporate progress take place?

The conference call to discuss financial results and recent corporate progress will be held on Thursday, March 7, 2024, at 4:30 pm ET.

Where can one access the listen-only webcast of the conference call?

The listen-only webcast of the conference call can be accessed under 'Events & Presentations' in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

How long will the recorded replay of the webcast be available?

A recorded replay of the webcast will be available shortly after the call's conclusion and archived on MacroGenics' website for 30 days following the call.